Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbidities and with psychiatric conditions. Results: Of the 1610 patients included, 82.4% were evaluable after 12 months with 25.1% of patients >75 years, 70.8% with relevant comorbidities and 42.4% with psychiatric conditions. During observation 45.8% patients experienced adverse events, 27.7% patients had adverse drug reactions and 9.2% patients had serious adverse events. The adverse events were those already described in the patients' information leaflet. The majority were mild or moderate and completely resolved and no differences were detected between the subgroup of patients. Clinically significant improvements were seen in the UPDRS motor score and in the UPDRS total score in ≥40% of patients, according to the criteria developed by Shulman et al. Conclusion: The SYNAPSES study confirms the good safety profile of safinamide even in special groups of patients. Motor complications and motor scores improved with clinically significant results in the UPDRS scale maintained in the long-term.

A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SynapSES trial

Mauri M.
Membro del Collaboration Group
;
2021-01-01

Abstract

Background: Safinamide modulates both dopaminergic and glutamatergic systems with positive effects on motor and non-motor symptoms of Parkinson's disease (PD). The drug utilization study SYNAPSES was designed to investigate the use of safinamide in routine clinical practice, as recommended by the European Medicines Agency. Objective: To describe the occurrence of adverse events in PD patients treated with safinamide in real-life conditions. Methods: The SYNAPSES trial is an observational, European, multicenter, retrospective-prospective cohort study. Patients were followed up to 12 months with analyses performed in the overall population and in patients aged >75 years, with relevant comorbidities and with psychiatric conditions. Results: Of the 1610 patients included, 82.4% were evaluable after 12 months with 25.1% of patients >75 years, 70.8% with relevant comorbidities and 42.4% with psychiatric conditions. During observation 45.8% patients experienced adverse events, 27.7% patients had adverse drug reactions and 9.2% patients had serious adverse events. The adverse events were those already described in the patients' information leaflet. The majority were mild or moderate and completely resolved and no differences were detected between the subgroup of patients. Clinically significant improvements were seen in the UPDRS motor score and in the UPDRS total score in ≥40% of patients, according to the criteria developed by Shulman et al. Conclusion: The SYNAPSES study confirms the good safety profile of safinamide even in special groups of patients. Motor complications and motor scores improved with clinically significant results in the UPDRS scale maintained in the long-term.
2021
MAO-B inhibitor; Parkinson's disease; Real-life evaluation; Safinamide
Abbruzzese, G.; Kulisevsky, J.; Bergmans, B.; Gomez-Esteban, J. C.; Kagi, G.; Raw, J.; Stefani, A.; Warnecke, T.; Jost, W. H.; Bergmans, B.; Bourgeois, P.; Cras, P.; de Klippel, N.; Dethy, S.; Franco, G.; Garraux, G.; Geens, K.; Jacquerye, P.; Jeanjean, A.; Santens, P.; Supiot, F.; van der Linden, C.; Blersch, W. K.; Delf, M.; Hellwig, B.; Herbst, H. P.; Kupsch, A.; Jost, W. H.; Lang, M.; Muhlack, S.; Nastos, I.; Oehlwein, C.; Schlegel, E.; Schwarz, J.; Warnecke, T.; Woitalla, D.; Abbruzzese, G.; Aguggia, M.; Avarello, T.; Barone, P.; Baruffaldi, R.; Belgrado, E.; Bentivoglio, A. R.; Bosco, D.; Calabresi, P.; Callegarini, C.; Cannas, A.; Centonze, D.; Ceravolo, R.; Colosimo, C.; Comi, C.; Contardi, S.; Cortelli, P.; Cossu, G.; D'Amelio, M.; de Pandis, M. F.; Denaro, A.; Di Lazzaro, V.; Fabbrini, G.; Gasparoli, E.; Guidi, M.; Iliceto, G.; Lopiano, L.; Manganotti, P.; Marconi, R.; Marini, C.; Marsala, S. Z.; Mauri, M.; Moleri, M.; Monge, A.; Morgante, F.; Negrotti, A.; Nordera, G.; Onofrj, M.; Pacchetti, C.; Padovani, A.; Pontieri, F. E.; Priori, A.; Quatrale, R.; Sensi, M.; Stefani, A.; Tamma, F.; Tessitore, A.; Tinazzi, M.; Vitale, C.; Volonte, M. A.; Zappia, M.; Zecchinelli, A. L.; Arbelo Gonzalez, J. M.; Bayes, A.; Blazquez, M.; Calopa Garriga, M.; Callen, A.; Campos Arillo, V.; Cubo, E.; de Fabregues, O.; Escalante Arroyo, S.; Espinosa Rosso, R.; Esquivel Lopez, A.; Freire, E.; Garcia Cobos, E.; Garcia Moreno, J. M.; Gomez-Esteban, J. C.; Gonzalez-Ardura, J.; Grandas Perez, F.; Kulisevsky, J.; Kurtis, M.; Juni, J.; Legarda, I.; Leiva, C.; Lopez Aristegui, N.; Lopez Manzanares, L.; Lozano, J. J.; Luquin, M. R.; Martinez Castrillo, J. C.; Marti Domenech, M. J.; Martinez, I.; Mata, M.; Mir Rivera, P.; Pascual Sedano, B.; Rodriguez Oroz, M. C.; Rodriguez Uranga, J. J.; Sanchez, S.; Santos Garcia, D.; Solano, B.; Vaamonde Gamo, J.; Accolla, E.; Bohlhalter, S.; Kalin, A.; Kagi, G.; Michelis, J.; Carrol, C.; Henderson, E.; Raha, S.; Raw, J.; Silva, N.; Silverdale, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2109526
 Attenzione

L'Ateneo sottopone a validazione solo i file PDF allegati

Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 36
social impact